Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3473 in Relapsed/Refractory Hematological Malignancies
NCT04412577Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3473 in hematologic malignancy, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose up to 31 days. Status: unknown.
02
Drugs
TQB3473
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04412577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412577.